Pomerantz LLP Investigates Anika Therapeutics Securities Fraud Claims

Pomerantz LLP is investigating claims of securities fraud against Anika Therapeutics, Inc. on behalf of investors. The investigation concerns whether Anika and its officers/directors have engaged in unlawful business practices. Anika issued a press release on July 30, 2025, announcing topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold for cartilage repair. The study did not meet its pre-specified co-primary endpoints.

New York, September 2, 2025 — Pomerantz LLP has initiated an investigation into claims of securities fraud against Anika Therapeutics, Inc. (NASDAQ: ANIK) on behalf of its investors. The investigation focuses on whether Anika and its officers or directors have engaged in unlawful business practices.

The inquiry follows a press release issued by Anika on July 30, 2025, announcing topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair. The press release stated that while Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by a higher subject dropout rate in the microfracture arm and missed visits during COVID, resulting in missing data and complicating statistical analysis [1].

Following the announcement, Anika's stock price fell by $3.06 per share, or 27.42%, to close at $8.10 per share on July 30, 2025 [1].

Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 to join the class action. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is renowned for its expertise in corporate, securities, and antitrust class litigation. The firm has a history of recovering multimillion-dollar damages on behalf of class members [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9519180/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-anika-therapeutics-inc-anik
[2] https://www.ainvest.com/news/pomerantz-investigates-anika-therapeutics-securities-fraud-allegations-2508/
[3] https://www.globenewswire.com/news-release/2025/08/26/3139619/0/en/ANIKA-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-Anika-Therapeutics-Inc-on-Behalf-of-Anika-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html